Overview

Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer

Status:
Completed
Trial end date:
2017-07-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the effects, good and/or bad, of standard of care therapy (docetaxel or paclitaxel) with or without the addition of 1-Methyl-D-tryptophan (referred to as indoximod) an experimental drug to find out which treatment is better.
Phase:
Phase 2
Details
Lead Sponsor:
NewLink Genetics Corporation
Treatments:
Albumin-Bound Paclitaxel
Docetaxel
Paclitaxel
Tryptophan